Suporn Chuncharunee

发表

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Vip Viprakasit, Ali T Taher, Maria Domenica Cappellini, 2012, Blood.

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

Vip Viprakasit, Ali T Taher, Dany Habr, 2013, American journal of hematology.

International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers

Mark Fogel, Ru San Tan, Dudley J Pennell, 2010, Journal of magnetic resonance imaging : JMRI.